lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-04. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
=== Signs and symptoms === The classic clinical syndrome for vitamin B6 deficiency is a seborrheic dermatitis-like eruption, atrophic glossitis with ulceration, angular cheilitis, conjunctivitis, intertrigo, abnormal electroencephalograms, microcytic anemia (due to impaired heme synthesis), and neurological symptoms of somnolence, confusion, depression, and neuropathy (due to impaired sphingosine synthesis). In infants, a deficiency in vitamin B6 can lead to irritability, abnormally acute hearing, and convulsive seizures. Less severe cases present with metabolic disease associated with insufficient activity of the coenzyme pyridoxal 5' phosphate (PLP). The most prominent of the lesions is due to impaired tryptophan–niacin conversion. This can be detected based on urinary excretion of xanthurenic acid after an oral tryptophan load. Vitamin B6 deficiency can also result in impaired transsulfuration of methionine to cysteine. The PLP-dependent transaminases and glycogen phosphorylase provide the vitamin with its role in gluconeogenesis, so deprivation of vitamin B6 results in impaired glucose tolerance.
=== Boers retreat === The set-piece period of the war now largely gave way to a guerrilla war, but one final operation remained. President Kruger and what remained of the Transvaal government had retreated to eastern Transvaal. Roberts, joined by troops from Natal under Buller, advanced against them, and broke their last defensive position at Bergendal on 26 August. As Roberts and Buller followed up along the railway line to Komatipoort, Kruger sought asylum in Portuguese East Africa (modern Mozambique). Some dispirited Boers did likewise, and the British gathered up much war material. However, the core of the Boer fighters under Botha easily broke back through the Drakensberg Mountains into the Transvaal highveld after riding north through the bushveld. As Roberts's army occupied Pretoria, the Boer fighters in the Orange Free State retreated into the Brandwater Basin, a fertile area in the south-east of the Republic. This offered only temporary sanctuary, as the mountain passes leading to it could be occupied by the British, trapping the Boers. A force under General Archibald Hunter set out from Bloemfontein to achieve this in July 1900. The hard core of the Free State Boers under De Wet, accompanied by President Steyn, left the basin early. Those remaining fell into confusion and most failed to break out before Hunter trapped them.
American molecular biologist at the Cold Spring Harbor Laboratory, who proposed the double helical structure of DNA, with Francis Crick. Nobel Prize in Physiology or Medicine (1962). Member Natl. Acad. Sci. USA
=== Luminous flux: watt equivalent === With the phaseout of the incandescent lamp in the United States and European Union in the early 21st century, manufacturers and sellers of more energy-efficient lamps have compared the visible light output of their lamps to commonly used incandescent lamp sizes with the watt equivalent or watt incandescent replacement (usually with a lowercase w as a unit symbol, as opposed to capital W for the actual wattage). 1 watt incandescent replacement corresponds to 15 lumens. Thus, a 72-watt halogen lamp, a 23-watt compact fluorescent lamp and a 14-watt light-emitting diode lamp, all of which emit 1500 lumens of visible light, are all marketed as "100 watt incandescent replacement" (100w).
US EPA: Per- and Polyfluoroalkyl Substances (PFAS) – Overview, regulatory actions, tools & resources Sustained Outrage Blog – C8 (PFOA) Category Archived 2010-04-02 at the Wayback Machine published by the Charleston Gazette Perfluorooctanoic Acid (PFOA); Fluorinated Telomers enforceable consent agreement development Perfluorinated substances and their uses in Sweden Chain of Contamination: The Food Link, Perfluorinated Chemicals (PFCs) Incl. PFOS & PFOA
Sources: en.wikipedia.org
In May 2024, Moody's Ratings issued a report expressing concerns with Maryland's fiscal stability, citing imminent structural deficits driven by programs including the Blueprint for Maryland's Future. In May 2025, Moody's decreased Maryland's bond rating from AAA to AA1, saying that while Maryland had addressed its budget problems "through a combination of tax increases and restraints on expenditures", the state was economically and fiscally underperforming other states with an AAA bond rating. Moody's report also predicted that Maryland would continue to underperform economically due to the state's "heightened vulnerability to shifting federal policies and employment, and its elevated fixed costs". At the same time, Fitch Ratings and S&P Global Ratings maintained Maryland's AAA rating, though Fitch similarly expressed concerns with the state's ability to fund the Blueprint. In May 2026, Maryland ended its relationship with Moody's, replacing it with the Kroll Bond Rating Agency. In December 2024, Moore endorsed a bill that would allow sales of beer and wine in grocery stores, calling Maryland's laws on alcohol sales "out of step with the rest of the country". However, he later signaled that he wouldn't include the bill in his administration's official priorities, instead preferring to focus on addressing the state's multi-billion dollar deficit during the 2025 legislative session.
=== Flagship facility === UPMC Presbyterian Shadyside is UPMC's primary flagship medical entity and represents the core of UPMC's academic, teaching, trauma, specialty and research-related facilities, serving as the system's primary academic hub and Pennsylvania's largest inpatient acute care hospital. UPMC Presbyterian Shadyside includes UPMC Presbyterian hospital and the physically conjoined UPMC Eye & Ear and UPMC Montefiore hospitals as well as the UPMC Western Psychiatric Hospital that also serves as the University of Pittsburgh's Thomas Detre Hall. These facilities are all located on the western side of the University of Pittsburgh's main campus in the Oakland neighborhood of Pittsburgh. The hospitals are also physically connected to the University of Pittsburgh School of Medicine's Scaife Hall, the University of Pittsburgh School of Nursing's Victoria Hall, Falk Clinic, three of the university's biomedical science towers, and the university's Lothrop Hall dormitory, all of which are surrounded by a variety of other academic facilities. UPMC Presbyterian Shadyside also encompasses the UPMC Shadyside hospital campus which includes the University of Pittsburgh Cancer Institute in the UPMC Hillman Cancer Center which are located near the university's Centre Plaza Apartments student housing. The UPMC Shadyside facilities are located in the adjacent neighborhood of Shadyside approximately 1.5 miles (2.4 km) from the Oakland-based hospitals and are connected by regular shuttle service.
==== Protecting groups ==== Methyl esters — Also removed by acid or pig liver esterase. Can be formed from diazomethane in diethyl ether, caesium carbonate and methyl iodide in N,N‑dimethylformamide, or methanol and catalytic trimethylsilyl chloride Benzyl esters — Also removed by hydrogenolysis. Benzhydryl esters — Same as benzyl, but easier to cleave tert-Butyl esters – Also removed by acid and some reductants. Can be formed from carboalkoxylation using isobutene in dioxane and catalytic sulfuric acid or under mild conditions via their silver carboxylate using tert-butyl iodide 2,6‑Dialkylphenols (e.g. 2,6-dimethylphenol, 2,6-diisopropylphenol, 2,6-di-tert-butylphenol) — Also removed in DBU-catalyzed high-pressure methanolysis at room temperature. Allyl esters — As with allyl ethers, also removed by diverse platinum complexes – connected with acid workup Silyl esters – Also removed by base and organometallic reagents. Orthoesters – Converted to standard ester by mild aqueous acid Oxazoline – Removed by strong hot acid (pH < 1, T > 100 °C) or alkali (pH > 12, T > 100 °C), but not e.g. LiAlH4, organolithium reagents or Grignard (organomagnesium) reagents
== Interactions == If diazepam is administered concomitantly with other drugs, it is recommended that attention be paid to the possible pharmacological interactions. Particular care is taken with drugs that potentiate the effects of diazepam, such as barbiturates, phenothiazines, opioids, and antidepressants. Diazepam does not increase or decrease hepatic enzyme activity and does not alter the metabolism of other compounds. No evidence has suggested that diazepam alters its metabolism with chronic administration. Agents with an effect on hepatic cytochrome P450 pathways or conjugation can alter the rate of diazepam metabolism. These interactions would be expected to be most significant with long-term diazepam therapy, and their clinical significance is variable.
Sources: en.wikipedia.org
Samson admitted that she was not familiar with the topic, but found it to be really interesting. She also explained that Mia has "a bit of tunnel vision" and feels that adopting a child will solve her problems, where Ari is more realistic about their situation. Samson believed Mia was using it as a way to channel her grief. Later scenes see Ari and Mia discussing adoption with John because he adopted his son, and while his experience is different from what Ari and Mia's would be, he gives them hope. The couple soon realise that Ari's criminal record might put a halt to their plans. Samson said "It just makes Mia more determined! Ari is quite worried about it from early on, but nothing is going to stop Mia..." In addition to this, Jasmine Delaney (Sam Frost) offers to sell the gym to Mia, which excites her as she would have something of her own and it will look good on the adoption application. The couple later become engaged, after Ari proposes to Mia. Barrett commented that her character is "ecstatically happy" for her mother and Ari, as she knows how much they love each other. Towards the end of 2021, producers introduced Chloe's biological father Matthew Montgomery (James Sweeny). This also led to further exploration of Mia's backstory, as it emerges that Matthew sexually assaulted her the night Chloe was conceived. A spokesperson for the serial told Sarah Ellis (Inside Soap) that Chloe has always seen Ari as a father figure because he has been in her life since she was young.
== Indications (biomarkers) == The most common biomarker for exposure to AzM is the inhibition of AChE. Also other esterase enzymes as CaE and BChE are inhibited by AzM. In general AzM exposure can be better detected by AChE inhibition than CaE inhibition. In amphibians and also zebrafish, AChE is a more sensitive biomarker for low AzM exposure-levels. As already mentioned in paragraph 7 “detoxification”, AzM can be metabolized into nontoxic dimethylated alkylphosphates (AP), with the help of CYP450 and glutathione. These APs are: dimethylphosphate (DM), dimethylthiophosphate (DMTP) and dimethyldithiophosphate (DMDTP). These three metabolites may be excreted into the urine and can be used as reliable biomarkers of exposure to AzM. However these metabolites are not specific to AzM, because other organophosphate pesticides might also be metabolized into the three alkylphosphates. The amount of erythrocyte acetylcholinesterase (RBE-AChE) in the blood can also be used as a biomarker of effect for AzM. According to Zavon (1965) RBC-AChE is the best indicator of AChE activity at the nerve synapse, because this closely parallels the level of AChE in the CNS and PNS. A depression of RBC-AChE will correlate with effects due to a rapid depression of AChE enzymes found in other tissues, this is due to the fact that both enzymes can be inhibited by AzM.
=== Shiley defective heart valves settlement (1994) === Pfizer purchased Shiley in 1979, at the onset of its Convexo-Concave valve ordeal, involving the Bjork–Shiley valve. Approximately 500 people died when defective heart valves fractured and, in 1994, Pfizer agreed to pay $10.75 million to settle claims by the United States Department of Justice that the company lied to get approval for the valves.
Instrumentation can control sampling, reagent use, reaction times, signal detection, calculation of results, and data management to yield a cost-effective automated process for diagnosis of infectious disease.
Iraq, which has this dynamic combination and much else besides, has not until recently been very much regarded as a power. But with the new discussions in OPEC, the ending of the Kurdistan war and the new round of fighting in Lebanon, its political voice is being heard more and more. The Baghdad regime is the first oil-producing government to opt for 100-per-cent nationalisation, a process completed with the acquisition of foreign assets in Basrah last December. It was the first to call for the use of oil as a political weapon against Israel and her backers. It gives strong economic and political support to the 'Rejection Front' Palestinians who oppose Arafat's conciliation and are currently trying to outface the Syrians in Beirut. He argued that the means through which the Baathist regime rose to power were similar to that of Iran: having crushed any political dissent and notions of an independent Kurdish state. He stated that the Ba'ath party "point to efforts made by the party press to stimulate criticism of revolutionary shortcomings" but that these "fall rather short of permitting any organised opposition". He claimed that Iraq defended this by claiming "that the country is surrounded by enemies and attacked by imperialist intrigue" but that this had led to the repression of Kurdish nationalists.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.